Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Amidst a backdrop of global trade policy uncertainty and mixed economic signals, the European market has shown resilience, with Germany's DAX Index rising by over 2% despite broader concerns impacting ...

Current health news highlights include Apollo Hospitals' AI investments to alleviate staff workload, Dr. Mehmet Oz's Medicare ...

Stocks entered a correction on Thursday as the S&P 500 index fell 10% from its recent peak after President Donald Trump escalated the trade war with 200% tariffs on European alcoholic beverages. This ...